Japanese company Kaken Pharmaceutical and US Elitra Pharmaceuticals
said yesterday that they are to collaborate on a multi-year
research project for the discovery and development of novel
anti-fungal drugs.
Danish company Novozymes announced yesterday that the US Department
of Energy (DOE) has approved the third year of funding for
Novozymes' three-year subcontract to develop more cost-efficient
enzymes for ethanol production.
Isis Innovation, the wholly-owned technology transfer company of
Oxford University, reports this week that researchers at the
university's Inorganic Chemistry laboratory have found that they
can intercalate a range of pharmaceutically...
France needs to invest more in the emerging 'revolutionary' science
of nanotechnologies if it is to remain competitive in this
promising field, a French parliamentary committee has recommended.
Large Scale Biology Corporation (LSBC) has started a research
collaboration with Novozymes Biotech to apply LSBC's gene shuffling
and molecular evolution technologies to genes of interest to
Novozymes Biotech.
The chemical cousin of vitamin A is thought to restore production
of a key protein, which has been damaged by cigarettes in the lungs
of former smokers, and protects the cells against lung cancer,
according to new findings published...
Danish vegetable oils and fats company Aarhus Oliefabrik announced
yesterday that together with Astion, it will increase the
development portfolio of BSP Pharma principally using oil from the
African shea nut.
Growing and steady interest in herbal supplements, particularly in
the US, is spurring demand for plant-derived chemicals. According
to a new report figures show that in the US growth is expected to
rise by 6.8 per cent annually in...
The structure of a key energy-releasing enzyme found in all animals
is designed to minimise free radical production, an international
team of researchers report in this week's Science.
Canadian drug development company Ecopia BioSciences on Monday
announced that it had filed patent applications for the first two
novel compounds using its proprietary drug discovery platform -
suggesting investments by the company...
